Ignite Creation Date:
2024-05-05 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 9:50 AM
Study NCT ID:
NCT00697229
Status:
COMPLETED
Last Update Posted:
2008-06-13
First Post:
2008-06-11
Brief Title:
Immunogenicity Reactogenicity of HBV-MPL Vaccine and Engerix-B in Healthy Adults Following 2 Different Schedules
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Study to Evaluate the Immunogenicity and Reactogenicity of GSK Biologicals MPL-Adjuvanted Recombinant Hepatitis B Vaccine in Comparison With Those of Engerix-B in Healthy Adult Volunteers Following 2 Different Schedules
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety immunogenicity and reactogenicity of MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix-B in healthy adult volunteers following two different schedules 0 2 months and 0 6 months
Detailed Description:
At the time of conduct of this study the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None